Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIL Therapy + Pembrolizumab in Advanced Breast Cancer
NCT06532812Phase 2Recruiting
- Sponsor
- Essen BioTech
- Start
- Aug 2024
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies, Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous tumor-infiltrating lymphocytes in breast cancer, sponsored by Essen BioTech. Primary endpoint: Adverse Events at 6 months. Started Aug 2024; status: recruiting.
02
Drugs
autologous tumor-infiltrating lymphocytes
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06532812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06532812.